cancer





About Mediscience Detection
History
Strategy
Business
Technical
product
clinical
Cancer

ABOUT MEDISCIENCE

About Mediscience click here

Method of Detection click here

Company History click here

Strategy click here

Business Development Marketing click here

Technical Information click here

Mediscience Technology Corp. is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy (the "Technology") to distinguish between malignant and normal or benign tissue.

We have successfully conducted both preclinical and clinical evaluations which support the value of our proprietary technology, which when fully developed, will be useful in the screening and diagnosis of cancer. We believe that our technology, if successfully developed, will have substantial commercial appeal due to its non-invasive character, its delivery of immediate, real time results and its enhanced diagnostic sensitivity and specificity.

Top of page

Method of Detection

Animal and human tissue contains molecules that fluoresce naturally when excited by light at certain wavelengths. Since the molecular and or structural makeup of tissue changes as it becomes cancerous, the Company's medical devices are able to detect a shift in the resulting native tissue fluorescence spectrum allowing it to distinguish between normal, pre-cancerous and cancerous tissue.

To see the slide presentation prepared by Mediscience and Sarnoff Corporation describing Fluorescence Imaging Technology click here..

Top of page

Company History and Key Recent Events

In March 1971, Cardiac Techniques, the predecessor of Mediscience Technology, was incorporated in the State of New Jersey as a provider of cardiac care medical monitoring services. In September 1971, it acquired Mediscience Corporation, a Delaware company with a then novel ambulatory cardiac events monitor, in a share exchange transaction. In November 1971, the assets of the newly acquired subsidiary were transferred in liquidation to Cardiac Techniques, which was re-named Mediscience Technology to reflect the corporate mission of expanding the scope of its diagnostics business.

In 1986 a decision was made to exit the cardiac monitoring business and explore opportunities in other areas. Mr. Peter Katevatis, then President of Mediscience Corp., identified medical optics as a high potential area, and in December 1988, he acquired Laser Diagnostics Instruments (LDI) and its seminal photonics patent "Method and Apparatus for Detecting Cancerous Tissue Using Visible Luminescence," from Dr. Robert Alfano in a tax free exchange of shares. Under the guidance of Mr. Katevatis, the company entered into a long-term research relationship with the City University of New York and Dr. Alfano (Distinguished professor of Science and Engineering, and director New York State Center for Advanced Technology for Ultra fast Materials and Lasers). From 1988 through 1998 the company funded research at the City University, generating over 30 patents in the areas of tissue spectroscopy and optical imaging with applications in cancer detection. During that period the company also partnered with and/or conducted research at leading medical institutions including the National Cancer Institute (NCI), Memorial-Sloan Kettering Cancer Center, New York Hospital Cornell Medical Center, Yale University Department of OBGYN, etc. The Company has validated its technology in both pre-clinical and clinical testing, and is now focused on commercialization.

In April 1999, the Company and the City University initiated a joint effort with Sarnoff Corporation of Princeton, NJ for the purpose of developing a commercial imaging system based on the Company's technology, and on the engineering background and expertise, and certain proprietary technology of Sarnoff.

In November 1999, the Company announced that it was seeking investment partners to support the funding of a joint effort between itself, Sarnoff Corporation, and the City University of New York to develop and commercialize an advanced, second generation version of its proprietary two-dimensional fluorescence imaging system for early cancer detection.

In August 2000, the Company and Sarnoff Corporation agreed in principle to form a Joint Venture to develop optical diagnostic products based on the Company's proprietary technology and using key enabling technologies and know-how proprietary to Sarnoff.

The Company headquarters are located at 1235 Folkstone Way Cherry Hill NJ. The Company presently operates as a virtual Company with two employees.

Top of page

Strategy

Our strategy is to develop one or more products for the non-invasive or minimally-invasive diagnosis of specific types of cancer which we ultimately plan to market worldwide. We believe that our Technology will be broadly applicable in cancer screening and diagnosis, however, each approved labeled indication is expected to require separate pre-marketing approval (a "PMA"), which will be both time-consuming and costly. We plan to carefully select and prioritize our targeted diagnostic indications to maximize the return on development and clinical investments. We regard our seminal patents (see Intellectual Property) as pioneering, blocking and dominant in the area of cancer diagnosis using fluorescence spectroscopy both in-vivo and in-vitro.

Top of page

Business Development Marketing

More than 120,000 new cancer cases are diagnosed annually in the United States. It is estimated that as many as 85 million people currently alive in the United States, nearly 1/3 of the population, will develop cancer during their lifetimes. Cancer care and treatment is estimated to cost $104 billion annually, $35 billion of which is estimated to be the direct cost of the disease.

Cancer therapy has progressed rapidly in recent years but the axiom that early diagnosis is critical for successful treatment for the majority of cancer types still remains true. Although several cancer screening techniques have been developed for the early indication of various types of cancer in humans, such as, mammography for breast cancer, PAP tests for cervical cancer, PSA tests for prostate cancer and chest x-rays for lung cancer, excision biopsy is still the "gold standard" for making a definitive cancer diagnosis and for cancer staging, i.e., determining the extent of the progression of the disease prior to mapping out the most appropriate course of therapy. The excision biopsy, however, often requires a significant amount of surgical intervention to collect an adequate tissue sample to make a proper diagnosis for staging determinations. The process can sometimes expose the patient to unnecessary risks, lengthy hospital stays, long recovery times, pain and discomfort and significant health care expense.

The Company's technology is believed to offer the potential of a less physically invasive method to diagnose and stage a variety of cancers without the excessive costs and potentially debilitating effects of biopsy.

Top of page

Technical Information

Numerous preclinical studies have been conducted to validate this technology and to demonstrate its ability to distinguish between normal, precancerous and cancerous tissues.(see Archives) In addition, a Phase I clinical feasibility study of the upper aerodigestive tract was carried out at Memorial Sloan-Kettering under the principal investigation of Stimson P. Schantz, M.D., Associate Professor of Surgery and Director of Cancer Prevention. In this study that the Company's CD Scan prototype product is able to distinguish between cancerous and normal tissue in the oral cavity. A Phase II clinical study in the upper aerodigestive tract is scheduled to begin when funding is available.

Top of page